# Cyclic Thrombocytopenia Misdiagnosed as Immune Thrombocytopenia (ITP): Diagnostic and Therapeutic Lessons

**Authors:** Sheilabi Seeburun, Eunseuk Lee, Sultan Salameh, Hussam Eltoukhy

PMC · DOI: 10.7759/cureus.97667 · Cureus · 2025-11-24

## TL;DR

A rare condition called cyclic thrombocytopenia was misdiagnosed as immune thrombocytopenia, leading to ineffective treatments and highlighting the need for better diagnostic awareness.

## Contribution

The paper presents a case emphasizing the diagnostic challenges of cyclic thrombocytopenia and proposes strategies to improve early detection and treatment.

## Key findings

- A 60-year-old woman's lifelong platelet variability was initially misdiagnosed as ITP.
- Adjusting avatrombopag dosage and considering CSA and danazol helped manage persistent platelet cycling.
- Regular platelet monitoring and increased clinical awareness can reduce misdiagnosis of CTP.

## Abstract

Cyclic thrombocytopenia (CTP) is a rare hematological disorder characterized by periodic fluctuations in platelet counts, resulting from diverse causes, including endocrine, immune-mediated, and idiopathic mechanisms. The cyclical nature of CTP often leads to misdiagnosis as immune thrombocytopenia (ITP), resulting in inappropriate long-term treatments and associated complications.

We report the case of a 60-year-old woman who experienced lifelong platelet variability, including during pregnancy and post-menopause, after being diagnosed with ITP in her early 20s. Over decades, she underwent extensive ITP-directed therapies, including corticosteroids, intravenous immunoglobulin (IVIG), rituximab, splenectomy, and thrombopoietin receptor agonists (TPO-RAs) like eltrombopag and avatrombopag. Persistent platelet cycling prompted a reevaluation of her condition, leading to a revised diagnosis of CTP. Her treatment was adjusted by increasing the avatrombopag dose, with additional consideration for cyclosporine A (CSA) and danazol if platelet cycling persisted. This case emphasizes the diagnostic challenges posed by CTP, which is often overlooked until ITP treatments fail. Regular biweekly platelet monitoring may facilitate earlier diagnosis. Better clinical awareness and clearer diagnostic guidelines are needed to reduce misdiagnosis and prevent unnecessary interventions.

## Linked entities

- **Chemicals:** eltrombopag (PubChem CID 135449332), avatrombopag (PubChem CID 9852519), cyclosporine A (PubChem CID 5284373), danazol (PubChem CID 28417)
- **Diseases:** cyclic thrombocytopenia (MONDO:0008556), immune thrombocytopenia (MONDO:0002048), ITP (MONDO:0008558)

## Full-text entities

- **Genes:** MPL (MPL proto-oncogene, thrombopoietin receptor) [NCBI Gene 4352] {aka C-MPL, CD110, MPLV, THCYT2, THPOR, TPOR}
- **Diseases:** hematological disorder (MESH:D006402), CTP (MESH:C536899), ITP (MESH:D016553)
- **Chemicals:** avatrombopag (MESH:C533238), CSA (MESH:D016572), danazol (MESH:D003613)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12643184/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12643184/full.md

## References

18 references — full list in the complete paper: https://tomesphere.com/paper/PMC12643184/full.md

---
Source: https://tomesphere.com/paper/PMC12643184